UCI Health

Orange, California 92868

7 studies enrolling now · 15 studies all time

What they study most

ALS, Advanced Cancer, Bladder Pain Syndrome, Cancer, Cervical Disc Disease, Crohn's Disease, Fatigue Related to Cancer Treatment, Heart Failure, Immunotherapy, Infectious Pneumonia, Interstitial Cystitis, Malignant Solid Tumors

Studies at this site

• Biofield Therapy for the Support of Immunotherapy-related Symptoms Among Adult Cancer Patients - A Pilot Study — Recruiting now
• A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease — Recruiting now
• Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM) — Recruiting now
• A Study of TAK-505 in Adults With Solid Tumors — Recruiting now
• Vitaccess Real MG Registry — Recruiting now
• Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma — Available (expanded access)
• A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation — Running, not enrolling
• A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation — Running, not enrolling
• Scalable Expanded Access With Analysis of Neurofilament and Other Biomarkers for Ibudilast in ALS — Available (expanded access)
• Reparixin add-on Therapy to Standard Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia — Stopped early
• A Study of Etavopivat in Patients With Thalassemia or Sickle Cell Disease — Completed
• A Phase 2 Study of IW-3300 for the Treatment of Bladder Pain in Subjects With Interstitial Cystitis/Bladder Pain Syndrome — Stopped early
• A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of Oral TACH101 in Participants With Advanced or Metastatic Cancer — Status unconfirmed
• A Clinical Trial Comparing the BAGUERA C to the Marketed Mobi-C® for the Treatment of Single Level Cervical Disc Disease — Status unconfirmed
• A Clinical Trial Comparing the BAGUERA C to the Marketed Mobi-C® for the Treatment of Cervical Disc Disease at 2 Contiguous Levels — Running, not enrolling